While biotech bets swing on trial data, this dividend payer gained 72% since 2024 By Investing.com RSS CTA
Amgen (AMGN) reported Q3 earnings of $6.45 per share, beating estimates by 12%, with revenue of $10.4B, up 9% YoY. The company's stock has gained 72% since late 2024, driven by strong commercial performance and a robust pipeline. Analysts have mixed views on its valuation, with a forward P/E of 19.9x. Amgen has raised its dividend for 16 consecutive years, yielding 2.2%.
How this was made
The 30-second read
Why it matters
The earnings beat could trigger short‑term buying, but longer‑term performance depends on pipeline execution and debt management.
Market read
First‑report earnings beat for a major biotech, likely to move the stock and influence sector sentiment.
What to watch
Risks from upcoming FDA warning letters and pricing pressure on key products could temper upside.
Background
Amgen is positioned as a cash‑generating biotech with a long dividend history, contrasting with more speculative peers.
Ticker impact
Amgen reported Q3 results on Nov 3, beating EPS estimates by 12% and revenue by 3.4% with $6.45 EPS and $10.4B revenue.
likely upward pressure as the market prices in the earnings beat and strong free cash flow
The beat is fresh, sizable, and comes from a large-cap biotech with a dividend streak, attracting both growth and income investors.
Market effects
Highlights the resilience of dividend‑paying biotech stocks versus high‑volatility peers.
U.S. biotech sector may see modest gains as Amgen outperforms peers.
Reinforces confidence in large‑cap pharma earnings amid broader market caution.
Counterpoint
Investors may be wary of potential biosimilar erosion and debt load despite the beat.
Key entities
- companyAmgen
Large‑cap biotech with dividend streak and strong cash flow.
